Effects of Thalidomide on VEGF and Quality of Life in Patients with Primary Hepatocellular Carcinoma after Transcatheter Arterial Chemoembotization
10.13241/j.cnki.pmb.2017.25.031
- VernacularTitle:沙利度胺对原发性肝癌介入后血管内皮生长因子及生存质量的影响
- Author:
Man AO
;
Xu XIAO
;
Yan YAN
;
Yan SHI
;
Xiying LV
- Keywords:
Hepatocelldiar carcinoma;
Thalidomide;
Vascular endothelial growth factor;
Quality of life;
Transcatheter arterial chemoembolization
- From:
Progress in Modern Biomedicine
2017;17(25):4928-4931,4951
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of thalidomide on vascular endothelial growth factor(VEGF) and quality of life in patients with primary hepatocellular carcinoma after transcatheter arterial chemoembotization.Methods:A total of 60 patients with HCC,who were treated with transcatheter arterial chemoembolization (TACE) in Affiliated Hospital of Chengde Medical University from January 2014 to January 2016,were randomly divided into group A (n=30)and group B (n=30).Group A was treated with Thalidomide in combination with TACE,oral 200 mg every night for 1 month;group B was treated with TACE alone.The levels of VEGF in the two groups were detected before treatment and 3 weeks after treatment;the quality of life of patients before treatment and 1 month after treatment was evaluated by quality of life scale (QOL);the weight of two groups before and after treatment and adverse reactions during treatment were compared.Results:There was no significant difference in VEGF levels between the two groups before treatment (P＞0.05).After treatment,the levels of VEGF in the two groups were higher than those before treatment,and the VEGF levels in the group A was significantly lower than that in the group B,the difference was statistically significant (P＜0.01).There was no significant difference in QOL score and body weight between the two groups before treatment (P＞0.05).The QOL scores of the two groups after treatment were lower than those before treatment,but the QOL scores of patients in group A were significantly higher than those in group B (P＜0.05).There was no significant difference in weight between the two groups before and after treatment (P＞0.05).In group A,1 patients (3.33％) had severe somnolence,2 (6.67％) patients stopped taking thalidomide due to severe dry mouth,and the remaining 27 patients were able to tolerate.Conclusion:Thalidomide combined with TACE in the treatment of patients with HCC can reduce the levels of VEGF and improve the quality of life of cancer patients,which is worthy to be popularized in clinic.
